Glycomine's GLM101 nears first placebo-controlled test in PMM2-CDG
The Phase 2b/3 POLAR trial is the first randomized, placebo-controlled study of GLM101 in a disease with no approved therapy, with topline ataxia data due in Q4 2026.
Executive Summary
- Glycomine has completed enrollment in a randomized, placebo-controlled study of GLM101 in a rare genetic disorder that currently has no approved treatment, setting up the first controlled test of whether the drug improves ataxia.
- The trial moved from recruiting to active and not recruiting on a normal timeline, and its primary completion date shifted later within the same reporting period, without any change to the enrollment target or the design.
- The prior clinical support for GLM101 comes from an open-label study without a placebo arm, so the coming readout is the first opportunity to see whether the ataxia benefit holds up against a control group.
- PMM2-CDG has no validated disease-modifying therapy, and the only other clinical-stage entrant identified in the indication is a small-molecule aldose reductase inhibitor with a different mechanism, leaving GLM101 without a direct comparator on modality or target.
The trial
POLAR (NCT06892288) is a global, randomized, double-blind, placebo-controlled study of GLM101, a liposomal mannose-1-phosphate substrate replacement therapy, in patients with PMM2-CDG. Glycomine said the study dosed 43 pediatric and adult patients, ages 4 to 47, across 15 sites in the United States, United Kingdom, and continental Europe. The trial targets 50 participants total, randomized between a GLM101 arm and a placebo arm. The primary endpoint is change in ataxia severity measured by the International Cooperative Ataxia Rating Scale (ICARS, a standardized ataxia-severity score) at 24 weeks. Twenty-two secondary endpoints cover additional ataxia and motor-function scales, pharmacokinetics, and safety through the end of the study. NCT06892288+1A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGNCT06892288Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDGApr 2, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The stake
PMM2-CDG is the most common congenital disorder of glycosylation, a rare genetic condition causing neurological and multisystem impairment, and more than 90% of patients present with ataxia as a core driver of disease burden, according to Glycomine. “The Phase 2b POLAR study will build on the results observed in our open-label Phase 2a study of GLM101, which demonstrated improvements in ataxia and other clinical endpoints with a favorable safety profile,” said Rose Marino, M.D., Glycomine's Chief Medical Officer. That Phase 2a study, conducted without a placebo arm, is the only prior clinical read on GLM101 in this population; GLM101 has also been tested in a Phase 1 healthy-volunteer study. POLAR is therefore the first controlled dataset the drug will generate. GlycomineGlycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDGApr 2, 2026
Operational status
The trial's status moved from recruiting to active, not recruiting on February 11, 2026, consistent with enrollment completion at the 50-patient target, with no change to that target recorded. Its primary completion date shifted from January 31, 2026 to September 30, 2026, a change logged February 27, 2026 alongside the status update. The trial has logged one primary-completion-date change and one eligibility-criteria modification since its March 2025 registration, a pattern the registry classifies as stable rather than frequently amended. Glycomine's regulatory filings show GLM101 holds Orphan Drug Designation in the US and EU, Rare Pediatric Disease Designation, and Fast Track Designation in the US, all announced April 2, 2026. NCT06892288+1A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGNCT06892288Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDGApr 2, 2026
The competitive field
PMM2-CDG carries no approved therapy, and the clinical-trial landscape in the indication is sparse: the only other active program identified is a Phase 3 study of epalrestat, a small-molecule aldose reductase inhibitor, a different mechanism and modality from GLM101's substrate-replacement approach. Glycomine also runs an open-label extension study of GLM101 (NCT06657859) alongside POLAR. With no other program sharing GLM101's mechanism or modality, POLAR's result will be read against an unvalidated-mechanism field rather than a direct rival's data: a controlled ICARS improvement that holds through the study's secondary ataxia and motor measures would be the type of result that distinguishes GLM101 in a field where no comparator has established a disease-modifying benefit.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.